CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis: Impact of FLT3 on OS Post-HCT for AML
Authors
Kwang Woo Ahn
Mahmoud Aljurf
+42 more
Joseph Harry Antin
Minoo Battiwalla
Martin Bornhauser
Donald Bunjes
Jean-Yves Cahn
Bruce Camitta
Yi-Bin Chen
Corey S. Cutler
Marcos de Lima
Abhinav Deol
Steven Devine
Robert Peter Gale
Siddhartha Ganguly
Mehdi Hamadani
Yoshihiro Inamoto
Madan Jagasia
Rammurti Kamble
Hanna Jean Khoury
John Koreth
Hillard M. Lazarus
Jane Liesveld
Mark R. Litzow
David I. Marks
Taiga Nishihori
Richard F. Olsson
Ran Reshef
Jacob M. Rowe
Ayman A. Saad
Wael Saber
Mitchell Sabloff
Brenda M. Sandmaier
Harry C. Schouten
Salyka Sengsayadeth
Thomas C. Shea
Robert J. Soiffer
Geoffrey L. Uy
Edmond K. Waller
Hai-Lin Wang
Dan Weisdorf
Peter H. Wiernik
Baldeep Wirk
Ann E. Woolfrey
Publication date
1 January 2016
Publisher
Doi
Cite
Abstract
BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild-type (WT) group (38% [95% confidence interval (CI), 30%-45%] vs 28% [95% CI, 24%-33%]; P = .04; relative risk, 1.60 [95% CI, 1.15-2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia-free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3-year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%-57%; WT group: 55%, 95% CI, 50%-60%; P = .20). CONCLUSIONS: The current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long-term survivors. Cancer 2016;122:3005-3014. © 2016 American Cancer Society
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Carolina Digital Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
cdr.lib.unc.edu:v118rk01q
Last time updated on 23/04/2020